Comparative Pharmacology
Head-to-head clinical analysis: ISOCLOR versus MYMETHAZINE FORTIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOCLOR versus MYMETHAZINE FORTIS.
ISOCLOR vs MYMETHAZINE FORTIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chlorpheniramine is an antihistamine (H1-receptor antagonist) that blocks the action of histamine, reducing allergy symptoms. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors, causing vasoconstriction in the nasal mucosa.
Mymethazine fortis is a phenothiazine derivative that exerts antipsychotic and antiemetic effects primarily by blocking postsynaptic dopamine D2 receptors in the mesolimbic system, as well as possessing anticholinergic, antihistaminergic, and alpha-adrenergic antagonistic properties.
Oral: 1 tablet (chlorpheniramine 4 mg / pseudoephedrine 60 mg) every 4-6 hours, not to exceed 4 tablets per 24 hours.
50 mg orally every 6 hours as needed for nausea and vomiting.
None Documented
None Documented
Approximately 2-4 hours in patients with normal renal function; prolonged to 8-12 hours in renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is 15-20 hours; in renal impairment (CrCl <30 mL/min), may extend to 30-40 hours, requiring dose adjustment.
Primarily renal; approximately 60-70% of a dose excreted unchanged in urine within 24 hours. Biliary/fecal excretion accounts for <10%.
Primarily renal (70-80% as unchanged drug and metabolites, with about 30% as unchanged); fecal (10-15%) via biliary elimination.
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine/Decongestant Combination